

Date: 10th August, 2022

To,
The Manager,
The BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchange is hereby informed that the Board of Directors of Alembic Limited at its meeting held today has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022.

We enclose herewith the following:

- 1) Consolidated Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022.
- 2) Standalone Unaudited Financial Results of the Company for the quarter ended on 30th June, 2022.
- 3) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 3:30 p.m. and the time of conclusion was 4:15 p.m.

We request you to kindly take the same on your record.

Thanking you.

Yours faithfully,

For Alembic Limited

Drigesh Mittal

Company Secretary

Encl.: A/a





ALEMBIC LIMITED

CIN:L26100GJ1907PLC000033

Regd.Office: Alembic Road, Vadodara 390 003

Ph:0265 2280550

 $www.alembic limited.com \\ Email: alembic.investors@alembic.co.in$

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2022

Rs. in Lakhs

		Rs. ii Quarter Ended Year E					
	0		Year Ended				
Sr.		30.06.2022	31.03.2022	30.06.2021	31.03.2022		
No	Particulars	(Unaudited)	(Audited)	(Unaudited)	(Audited)		
1	Revenue from Operations	2,209	1,824	2,106	7,822		
2	Other Income	70	440	173	8,918		
3	Total Income	2,280	2,264	2,278	16,740		
4	Expenses						
4	Cost of Materials Consumed	196	204	234	85		
	Cost of Construction	461	255	248	1,16		
	Changes in Inventories of Finished Goods and WIP	(2)	(34)	304	24		
	Employee Benefit Expenses	621	545	547	2,14		
	Finance Costs	11	10	10	3		
	Depreciation and amortisation expense	167	140	113	48		
	Other Expenses	392	562	341	2,02		
	Total Expenses	1,845	1,682	1,797	6,95		
5	Profit Before Tax	434	582	481	9,78		
•							
6	Tax Expenses	34	153	88	1,16		
	Current Tax	15	(23)	8	2		
	Deferred Tax Short ((Freeze) Provision of earlier years		(14)	-	(1		
7	Short / (Excess) Provision of earlier years Net Profit after tax for the Period	385	465	384	8,61		
8	Share of Associate's Profit/(Loss)	(2,241)	(374)	4,522	13,58		
9	Net Profit after tax and Share of Associate's Profit	(1,855)	91	4,906	22,20		
10	Other Comprehensive Income A (i) Items that will not be reclassified to Profit or (Loss)	(7,401)	878	(5,548)	11,89		
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	841	(98)	650	(1,34		
	B (i) Items that will be reclassified to Profit or (Loss)	179	83	53	1		
11	Total Comprehensive Income/(Loss) for the Period	(8,237)	954	62	32,8		
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.		
13	Other Equity (excluding Revaluation Reserve)				1,89,5		
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	(0.72)	0.04	1.91	8.		





Segment	wise	Conso	lidated	Revenue	and	Resul	ts

	Segment wise Consolidated Revenue and Results		Year Ended			
		0	Quarter Ended			
Sr.		30.06.2022	31.03.2022	30.06.2021	31.03.2022	
No	Particulars	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Segment Revenue					
	Revenue from Operations					
	a. Active Pharmaceutical Ingredients Business	729	698	1,092	3,227	
	b. Real Estate Business	1,481	0 1,125	1,013	4,595	
	Total Income from Operations (Net)	2,209	1,824	2,106	7,822	
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each					
	segment)					
	a. Active Pharmaceutical Ingredients Business	129	202	141	525	
	b. Real Estate Business	353	323	277	1,162	
	Total	482	525	418	1,687	
	Unallocable Income and Expenditure					
	(i) Interest Expense	(11)	(10)	(10)	(39)	
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	(49)	(57)	69	7,960	
	(iii) Other Income / (Expense)	13	124	4	178	
	Total Profit Before Tax	434	582	481	9,786	
3	Segment Assets					
	a. Active Pharmaceutical Ingredients Business	14,998	14,883	15,115	14,883	
	b. Real Estate Business	28,199	27,248	22,416	27,248	
	c. Unallocated	2,12,125	2,21,065	2,02,840	2,21,065	
	Total	2,55,321	2,63,195	2,40,370	2,63,195	
4	Segment Liabilities					
	a. Active Pharmaceutical Ingredients Business	1,963	1,752	1,896	1,752	
	b. Real Estate Business	6,590	5,533	4,661	5,533	
	c. Unallocated	5,347	6,251	4,048	6,251	
	Total	13,900	13,537	10,605	13,537	

Notes:

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The figures for quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2022 and year to date unaudited figures up to the third quarter ended 31st December 2021.
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Chirayu Amin Chairman

Re In Lakhe

Place: Vadodara

Date: 10th August, 2022



ALEMBIC LIMITED

CIN:L26100GJ1907PLC000033

Regd.Office: Alembic Road, Vadodara 390 003

Ph:0265 2280550

 $www. alembic limited. com \\ Email: alembic. investors@alembic. co. in$

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2022

Rs. in Lakhs

Т			Year Ended		
	0	30.06.2022	30.06.2021	31.03.2022	
Sr. No.	Particulars	(Unaudited)	31.03.2022 (Audited)	(Unaudited)	(Audited)
NO.	Particulars	(Ollaudited)	(Addited)	(Orladdited)	(riddiced)
1	Revenue from Operations	2,113	1,740	2,062	7,597
2	Other Income	71	433	173	8,909
3	Total Income	2,184	2,172	2,235	16,506
3	Total income	2,201			
4	Expenses				
	Cost of Materials Consumed	196	204	234	853
	Cost of Construction	461	255	248	1,164
	Changes in Inventories of Finished Goods and WIP	(2)	(34)	304	246
	Employee Benefit Expenses	621	545	547	2,147
	Finance Costs	4	3.	7	23
	Depreciation and amortisation expense	157	131	104	450
	Other Expenses	345	492	319	1,896
	Total Expenses	1,782	1,596	1,764	6,779
	Total Expenses				
5	Profit Before Tax	403	577	471	9,728
6	Tax Expenses Current Tax	24	152	88	1,150
	Deferred Tax	15	(23)	8	21
	Short / (Excess) Provision of earlier years		(15)	-	(15)
7	Net Profit after tax for the Period	363	462	375	8,571
	V				
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or (Loss)	(7,373)	972	(5,392)	12,009
	(ii) Income tax relating to items that will not be reclassified to				4.004
	Profit or (Loss)	841	(115)	624	(1,364)
9	Total Comprehensive Income/(Loss) for the Period	(6,169)	1,319	(4,394)	19,217
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				41,294
	Street Later (character)				
12		0.14	0.18	0.15	3.34
	Basic & Diluted (In Rs.)				





Sr.			Year Ended		
No.	Particulars	30.06.2022	31.03.2022	30.06.2021	31.03.2022
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	729	698	1,092	3,227
	b. Real Estate Business	1,384	1,041	969	4,371
	Total Income from Operations (Net)	2,113	1,740	2,062	7,597
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each				
	segment)				
	a. Active Pharmaceutical Ingredients Business	129	202	141	525
	b. Real Estate Business	314	312	264	1,088
	Total	443	514	406	1,613
	Unallocable Income and Expenditure				
	(i) Interest Expense	(4)	(3)	(7)	。 (23)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	(49)	(57)	69	7,960
	(iii) Other Income / (Expense)	13	124	4	178
	Total Profit Before Tax	403	577	471	9,728
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	14,998	14,883	15,115	14,883
	b. Real Estate Business	27,422	26,434	21,710	26,434
	c. Unallocated	66,252	73,102	51,836	73,102
	Total	1,08,671	1,14,419	88,661	1,14,419
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	1,963	1,752	1,896	1,752
	b. Real Estate Business	6,075	4,972	4,434	4,972
	c. Unallocated	5,417	6,309	4,043	6,309
	Total	13,456	13,034	10,373	13,034

Notes:

- 1 The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- 2 The figures for quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2022 and year to date unaudited figures up to the third quarter ended 31st December 2021.
- 3 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

For Alembic Limited

Chirayu Amin Chairman

Place : Vadodara

Date: 10th August, 2022





Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing bligations and Disclosure Requirements) Regulations, 2015, to the extent applicable

VADODARA: The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007

• Tel: +91 265 234 3483, +91 265 235 4359 • Email: vadodara@cnkindia.com

MUMBAI - HO: 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. • Tel: +91 22 6623 0600

- 4. The statement includes results of the following entities:
 - i. Alembic City Limited (Subsidiary)
 - ii. Alembic Pharmaceuticals Limited (Associate)
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 390.16 lakhs, total net loss after tax of Rs. 41.23 Lakhs and total comprehensive loss of Rs. 41.38 Lakhs for the quarter ended-30th June, 2022. The unaudited consolidated financial results also include the Group's share of net loss after tax of Rs. 2,240.90 Lakhs and total comprehensive loss of Rs. 2,089.93 lakhs (after adjusting impact of qualified opinion in the audit report on consolidated financial results) quarter ended 30th June, 2022, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP
Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah

Partner

Membership No.042005

Place: Vadodara

Date: 10th August, 2022

UDIN: 22042005AOSDWC6181



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

- 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of Alembic Limited ("the Company") for the quarter ended 30th June, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007

Tel: +91 265 234 3483, +91 265 235 4359 • Email : vadodara@cnkindia.com

MUMBAI - HO: 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. • Tel: +91 22 6623 0600

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Alok Shah

Partner

Membership No.042005

Place: Vadodara

Date: 10th August, 2022

UDIN: 22042005AOSDEY7170